

Harald Hefter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7693293/publications.pdf>

Version: 2024-02-01

51
papers

959
citations

430754

18
h-index

454834

30
g-index

51
all docs

51
docs citations

51
times ranked

685
citing authors

#	ARTICLE	IF	CITATIONS
1	Classification of posture in poststroke upper limb spasticity. <i>International Journal of Rehabilitation Research</i> , 2012, 35, 227-233.	0.7	95
2	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. <i>Neurology</i> , 2019, 92, e48-e54.	1.5	95
3	Does tremor pace repetitive voluntary motor behavior in parkinson's disease?. <i>Annals of Neurology</i> , 1991, 30, 172-179.	2.8	88
4	Neurological impairment and recovery in Wilson's disease: evidence from PET and MRI. <i>Journal of the Neurological Sciences</i> , 1996, 136, 129-139.	0.3	57
5	His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype. <i>European Journal of Human Genetics</i> , 1998, 6, 616-623.	1.4	56
6	Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins—a single cohort 4-year follow-up study. <i>BMJ Open</i> , 2012, 2, e000646.	0.8	47
7	Coordination between breathing and forearm movements during sinusoidal tracking. <i>European Journal of Applied Physiology</i> , 2000, 81, 288-296.	1.2	41
8	Evaluation of the Symptomatic Treatment of Residual Neurological Symptoms in Wilson Disease. <i>European Neurology</i> , 2010, 64, 83-87.	0.6	38
9	High Botulinum Toxin—Neutralizing Antibody Prevalence Under Long—Term Cervical Dystonia Treatment. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 500-506.	0.8	37
10	Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. <i>Journal of Neural Transmission</i> , 2014, 121, 513-519.	1.4	31
11	A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. <i>BMJ Open</i> , 2011, 1, e000196-e000196.	0.8	29
12	Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German—Austrian open-label post-marketing surveillance prospective study. <i>Journal of the Neurological Sciences</i> , 2014, 337, 86-90.	0.3	29
13	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2016, 13, 278.	3.1	23
14	Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study. <i>Journal of Neurology</i> , 2020, 267, 1340-1347.	1.8	22
15	Electrophysiological motor testing, MRI findings and clinical course in AIDS patients with dementia. <i>Journal of Neurology</i> , 1993, 240, 439-445.	1.8	21
16	Focal brain lesions in patients with AIDS: Aetiologies and corresponding radiological patterns in a prospective study. <i>Journal of Neurology</i> , 1995, 242, 69-74.	1.8	21
17	Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 63-67.	1.1	20
18	Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature. <i>Toxins</i> , 2020, 12, 499.	1.5	20

#	ARTICLE	IF	CITATIONS
19	Long-term outcome of neurological Wilson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 48-53.	1.1	19
20	Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. <i>Frontiers in Neurology</i> , 2020, 11, 104.	1.1	19
21	Improvement of upper trunk posture during walking in hemiplegic patients after injections of botulinum toxin into the arm. <i>Clinical Biomechanics</i> , 2017, 43, 15-22.	0.5	14
22	Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641989207.	1.5	14
23	Long-term adherence and response to botulinum toxin in different indications. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 15-28.	1.7	11
24	Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy. <i>Frontiers in Neurology</i> , 2020, 11, 588395.	1.1	10
25	Stavudine and the peripheral nerve in HIV-1 infected patients. <i>Journal of Neurology</i> , 1999, 246, 211-217.	1.8	9
26	Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins. <i>Frontiers in Neurology</i> , 2021, 12, 636590.	1.1	9
27	Impact of posterior deep neck muscle treatment on cervical dystonia: Necessity to differentiate between abnormal positions of head and neck. <i>Basal Ganglia</i> , 2012, 2, 103-107.	0.3	7
28	The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia. <i>Journal of Neurology</i> , 2021, 268, 206-213.	1.8	7
29	The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany. <i>Toxins</i> , 2021, 13, 101.	1.5	7
30	Wilson's Disease. <i>CNS Drugs</i> , 1994, 2, 26-39.	2.7	6
31	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 782.	1.1	6
32	Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson's Disease: Six Cases and Literature Review. <i>Toxins</i> , 2021, 13, 241.	1.5	6
33	The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia. <i>Toxins</i> , 2021, 13, 22.	1.5	6
34	Mild gait impairment in long-term treated patients with neurological Wilson's disease. <i>Annals of Translational Medicine</i> , 2019, 7, S57-S57.	0.7	5
35	Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure. <i>Toxins</i> , 2022, 14, 44.	1.5	5
36	A Novel Multiple-Cue Observational Clinical Scale for Functional Evaluation of Gait After Stroke – The Stroke Mobility Score (SMS). <i>Medical Science Monitor</i> , 2020, 26, e923147.	0.5	4

#	ARTICLE	IF	CITATIONS
37	Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA. <i>Toxins</i> , 2020, 12, 677.	1.5	3
38	The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia. <i>Toxins</i> , 2021, 13, 493.	1.5	3
39	Mildly Impaired Foot Control in Long-Term Treated Patients with Wilson's Disease. <i>Journal of Functional Morphology and Kinesiology</i> , 2022, 7, 5.	1.1	3
40	Different Response Behavior to Therapeutic Approaches in Homozygotic Wilson's Disease Twins with Clinical Phenotypic Variability: Case Report and Literature Review. <i>Genes</i> , 2022, 13, 1217.	1.0	3
41	Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199820.	0.4	2
42	Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop. <i>Toxins</i> , 2021, 13, 466.	1.5	2
43	Pushing during walking in adult patients after hemispheric stroke. <i>Physical Medicine and Rehabilitation Research</i> , 2020, 5, .	0.1	2
44	The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation: A Monocentric Cross-Sectional Pilot Study. <i>Medicina (Lithuania)</i> , 2022, 58, 88.	0.8	2
45	The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia. <i>Journal of Neurology</i> , 2022, 269, 5991-6002.	1.8	2
46	High prevalence of neutralizing antibodies in BoNT/A long-term treated patients with focal dystonia and spasticity. <i>Toxicon</i> , 2016, 123, S38-S39.	0.8	1
47	Analysis of Running in Wilson's Disease. <i>Sports</i> , 2022, 10, 11.	0.7	1
48	The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication. <i>Medicina (Lithuania)</i> , 2022, 58, 935.	0.8	1
49	Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report. <i>Toxins</i> , 2021, 13, 423.	1.5	0
50	Analysis of Single-Leg Hopping in Long-Term Treated Patients with Neurological Wilson's Disease: A Controlled Pilot Study. <i>Medicina (Lithuania)</i> , 2022, 58, 249.	0.8	0
51	Clinical Relevance of Neutralizing Antibodies in Botulinum Neurotoxin Type A. , 0, , .		0